KIYATEC & Drug Discovery

KIYATEC is working passionately to deliver broadly applicable 3D cell-based assays for use in preclinical drug discovery, specifically toxicity and efficacy evaluation of new drug compounds. As a world leader in segregated 3D co-culture, KIYATEC's 3DKUBE™ technology provides the means for creating advanced in vitro models using human cells in a dynamic and cost-effective platform. Check out our drug discovery contract service page to learn how KIYATEC can assist with your preclinical needs today.

Trends in Drug Discovery

The world of drug discovery has experienced a growing innovation gap with increases in annual R&D spending while the number of new drug approvals (NMEs) remain stagnant¹. Evidence has demonstrated that traditional preclinical drug discovery methods have limitations in predicting success of a new compound prior to entering human clinical trials, the most

expensive aspect of new drug development. Attrition rates during all clinical trial phases translate to only 12% of the drugs that enter human trials actually achieve U.S. FDA approval and commercial launch². A study of drug attrition from 1991-2000 noted the two most prevalent causes being lack of efficacy and toxicity³. Drug discovery and development is an expensive proposition due in part to the lack of advanced preclinical models needed to capture drug failures earlier in the process prior to entering first-in-man.

¹ Burrill & Co.; ² SM Paul, et al. Nature Reviews Drug Discovery 2010.; ³ I Kola, J Landis. Nature Reviews Drug Discovery 2004.

Collaborative Partnership for Success

KIYATEC has joined a select group of private industry partners in collaboration with the Institute for Translational Oncology Research (ITOR) of Greenville Hospital System University Medical Center. As a phase one clinical site, ITOR's Clinical Research Unit manages an average of 20 active clinical trials, including a number of first-in-man studies. As a result of the partnership, KIYATEC has taken the next step to physically relocate the company's R&D operations within the ITOR Innovation Zone laboratory space. Connectivity with pharmaceutical partners and the clinical center provides valuable feedback and insights necessary to effectively translate the company's core technology into productive tools useful in the preclinical stages of drug discovery.